Lisinopril
ACE Inhibitor for High Blood Pressure, Heart Failure and Kidney Protection
Quick Facts About Lisinopril
Key Takeaways About Lisinopril
- Proven cardiovascular and renal protection: Lisinopril effectively lowers blood pressure and reduces the risk of stroke, heart attack, heart failure progression, and diabetic kidney disease
- Dry cough is a common side effect: Approximately 5–10% of patients develop a persistent dry cough due to increased bradykinin levels – switching to an ARB resolves this
- Contraindicated in pregnancy: Lisinopril must not be used during pregnancy, especially in the second and third trimesters, as it can cause serious harm to the unborn baby
- Risk of angioedema: Seek immediate medical attention if you experience swelling of the face, lips, tongue, or throat while taking lisinopril – this is a rare but potentially life-threatening reaction
- Monitor potassium levels: Lisinopril can increase blood potassium levels (hyperkalaemia), particularly when used with potassium supplements, potassium-sparing diuretics, or in patients with kidney impairment
What Is Lisinopril and What Is It Used For?
Lisinopril is an ACE inhibitor (angiotensin-converting enzyme inhibitor) that relaxes and widens blood vessels, lowering blood pressure and reducing the workload on the heart. It is prescribed to treat high blood pressure (hypertension), heart failure, short-term recovery after a heart attack, and kidney disease in patients with type 2 diabetes and hypertension.
Lisinopril belongs to a group of medicines known as ACE inhibitors. It works by blocking the angiotensin-converting enzyme (ACE), which normally converts angiotensin I into angiotensin II – a powerful vasoconstrictor (a substance that narrows blood vessels). By preventing the formation of angiotensin II, lisinopril causes blood vessels to relax and dilate, reducing peripheral vascular resistance and lowering blood pressure. It also decreases the release of aldosterone, a hormone that causes the body to retain sodium and water, further contributing to blood pressure reduction.
In patients with high blood pressure (hypertension), lisinopril reduces the resistance in blood vessels, allowing blood to flow more easily. This reduction in blood pressure decreases the long-term strain on the heart, blood vessels, kidneys, and brain, helping to prevent serious complications including heart attack, stroke, kidney failure, and heart failure. The European Society of Cardiology (ESC), the American Heart Association (AHA), and the National Institute for Health and Care Excellence (NICE) all recommend ACE inhibitors as first-line treatment for hypertension, particularly in younger patients and those with diabetes or chronic kidney disease.
In patients with heart failure, the heart is unable to pump blood efficiently enough to meet the body's needs. Lisinopril reduces the workload on the failing heart by lowering blood pressure and reducing fluid retention. Large clinical trials, including the ATLAS trial, have demonstrated that ACE inhibitors improve symptoms, reduce hospitalisations, and extend survival in patients with heart failure. Lisinopril is typically used in combination with other heart failure medications, including beta-blockers, diuretics, and mineralocorticoid receptor antagonists.
Lisinopril is also used for short-term treatment after a heart attack (myocardial infarction). When started within 24 hours of a heart attack, ACE inhibitors help prevent adverse remodelling of the heart muscle and reduce the risk of subsequent heart failure and death. The landmark GISSI-3 trial demonstrated significant survival benefits with early lisinopril use after acute myocardial infarction.
In patients with type 2 diabetes and hypertension, lisinopril provides an additional benefit of protecting the kidneys. ACE inhibitors reduce pressure within the tiny blood vessels of the kidneys (the glomeruli), slowing the progression of diabetic nephropathy. This makes lisinopril a particularly valuable choice for patients who have both high blood pressure and diabetes, as it treats the blood pressure while simultaneously offering renal protection.
Lisinopril was first approved for medical use in 1987 and is included on the World Health Organization's List of Essential Medicines, recognising its importance as a cornerstone of cardiovascular therapy worldwide. Unlike many other ACE inhibitors (such as enalapril or ramipril), lisinopril is not a prodrug – it does not require activation by the liver, which can be an advantage in patients with liver impairment. It is available in numerous generic formulations, making it widely accessible and affordable.
What Should You Know Before Taking Lisinopril?
Before starting lisinopril, inform your doctor about all your medical conditions, especially any history of angioedema, kidney disease, liver disease, diabetes, or if you are pregnant or breastfeeding. Lisinopril is strictly contraindicated in pregnancy and in patients with a history of ACE inhibitor-related angioedema.
Contraindications
You should not take lisinopril if any of the following apply to you:
- Allergy to lisinopril or any other ACE inhibitor – symptoms of allergic reaction may include rash, itching, swelling, or difficulty breathing
- History of angioedema related to previous ACE inhibitor treatment – angioedema is a sudden swelling beneath the skin (similar to hives) that can affect the face, lips, tongue, throat, arms, or legs. This can be life-threatening if the airway is involved
- Hereditary or idiopathic angioedema – if you have a personal or family history of angioedema unrelated to ACE inhibitors, this medicine could trigger an episode
- Pregnancy, especially in the second and third trimesters – ACE inhibitors can cause serious birth defects, kidney damage, low amniotic fluid, and foetal death. Lisinopril should also be avoided in early pregnancy when possible
- Concurrent use with sacubitril/valsartan (Entresto) – this combination significantly increases the risk of angioedema. You must wait at least 36 hours after stopping sacubitril/valsartan before starting lisinopril, and vice versa
- Concurrent use with aliskiren in patients with diabetes or moderate-to-severe kidney impairment – dual blockade of the renin-angiotensin system increases the risk of hypotension, hyperkalaemia, and acute kidney injury
Warnings and Precautions
Talk to your doctor or pharmacist before taking lisinopril if you have or have had any of the following conditions:
- Kidney disease or renal artery stenosis (narrowing of the blood vessels supplying the kidneys) – lisinopril is excreted by the kidneys, and impaired kidney function may require dose adjustment. In bilateral renal artery stenosis, ACE inhibitors can cause acute kidney failure
- Liver disease – although lisinopril is not metabolised by the liver, rarely ACE inhibitors have been associated with a syndrome beginning with cholestatic jaundice and progressing to fulminant hepatic necrosis
- Heart valve disease or hypertrophic cardiomyopathy – the blood pressure-lowering effect may be pronounced and require careful monitoring
- Recent heart attack with unstable haemodynamics – careful blood pressure monitoring is essential
- Low blood pressure (hypotension) – particularly common at the start of treatment, in patients taking diuretics, or in those who are dehydrated
- Diabetes – lisinopril may enhance the blood sugar-lowering effect of insulin and oral antidiabetic agents; blood glucose monitoring is recommended
- Connective tissue disease (e.g. systemic lupus erythematosus, scleroderma) – increased risk of neutropenia and agranulocytosis with ACE inhibitors
- Black patients – ACE inhibitors may be less effective at lowering blood pressure in Black patients and carry a higher risk of angioedema in this population. A calcium channel blocker or thiazide diuretic may be preferred as initial therapy
- Patients undergoing dialysis with high-flux membranes or LDL apheresis – anaphylactoid reactions have been reported
- Patients undergoing desensitisation therapy (e.g. for bee or wasp venom allergy) – increased risk of anaphylactoid reactions
- Before surgery or anaesthesia – inform your surgeon, anaesthetist, or dentist that you are taking lisinopril, as the medicine may enhance the hypotensive effects of anaesthetic agents
Angioedema (swelling of the face, lips, tongue, throat, arms, or legs) can occur at any time during treatment with lisinopril. Seek immediate emergency medical attention if you experience sudden swelling of the face, difficulty breathing, or difficulty swallowing. Angioedema involving the tongue, glottis, or larynx can obstruct the airway and may be fatal. Patients of African descent have a higher risk of developing ACE inhibitor-related angioedema.
Pregnancy and Breastfeeding
Lisinopril must not be used during pregnancy. ACE inhibitors taken during the second and third trimesters are known to cause serious developmental toxicity, including reduced kidney function in the foetus, low amniotic fluid (oligohydramnios), skull ossification defects, and in severe cases, neonatal death. Even in early pregnancy, lisinopril should be avoided unless there is no suitable alternative.
If you discover you are pregnant while taking lisinopril, stop the medication immediately and contact your doctor. Your doctor will recommend a safer alternative for blood pressure control during pregnancy, such as labetalol, methyldopa, or nifedipine (extended-release).
Lisinopril is not recommended during breastfeeding, particularly for mothers of premature or newborn infants. If you need to take an ACE inhibitor while breastfeeding, your doctor will assess the benefits against the potential risks to your baby and may recommend an alternative treatment.
Driving and Operating Machinery
Lisinopril can occasionally cause dizziness, lightheadedness, or fatigue, particularly at the start of treatment, after a dose increase, or in combination with other blood pressure-lowering medications. If you experience any of these symptoms, you should not drive or operate machinery until you know how the medicine affects you. These effects are most common during the first few days of treatment and usually improve with continued use.
How Does Lisinopril Interact with Other Drugs?
Lisinopril can interact with several important medications, including potassium supplements, potassium-sparing diuretics, NSAIDs, lithium, aliskiren, and sacubitril/valsartan. These interactions can lead to dangerously high potassium levels, kidney damage, or excessive blood pressure lowering. Always tell your doctor about all medications you are taking.
Unlike many other ACE inhibitors, lisinopril is not significantly metabolised by liver enzymes and does not interact with the cytochrome P450 system. However, it has important pharmacodynamic interactions, particularly with drugs that affect the renin-angiotensin-aldosterone system (RAAS), potassium balance, or kidney function. The following tables summarise the most clinically significant interactions.
Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Sacubitril/Valsartan (Entresto) | Heart failure medication (ARNI) | Significantly increased risk of angioedema due to dual inhibition of neprilysin and ACE | Contraindicated. Wait at least 36 hours between switching |
| Aliskiren | Direct renin inhibitor | Dual RAAS blockade increases risk of hypotension, hyperkalaemia, and kidney failure | Contraindicated in diabetes or renal impairment. Avoid in all patients if possible |
| Potassium supplements / K-sparing diuretics (spironolactone, amiloride, eplerenone) | Potassium-affecting agents | Risk of life-threatening hyperkalaemia (dangerously high potassium levels) | Use only under close medical supervision with regular potassium monitoring |
| Lithium | Mood stabiliser (psychiatric medication) | Lisinopril reduces renal clearance of lithium, increasing blood lithium levels and risk of toxicity | Monitor lithium levels closely. Dose adjustment usually required |
Moderate Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| NSAIDs (ibuprofen, naproxen, diclofenac) and high-dose aspirin (>3 g/day) | Anti-inflammatory painkillers | May reduce the blood pressure-lowering effect of lisinopril and increase the risk of kidney damage and hyperkalaemia | Use the lowest NSAID dose for the shortest time. Monitor kidney function and blood pressure |
| ARBs (valsartan, irbesartan, telmisartan) | Angiotensin receptor blockers | Dual RAAS blockade increases risk of hypotension, hyperkalaemia, and renal impairment | Generally avoid combining ACE inhibitors with ARBs |
| Trimethoprim / Co-trimoxazole | Antibiotics | Trimethoprim impairs renal potassium excretion, increasing risk of hyperkalaemia when combined with ACE inhibitors | Monitor potassium levels within 48 hours of starting the antibiotic |
| Ciclosporin | Immunosuppressant | Both drugs increase potassium levels; combined use increases hyperkalaemia risk | Monitor potassium levels closely |
| Heparin | Anticoagulant | Heparin can suppress aldosterone production, adding to the potassium-retaining effect of lisinopril | Monitor potassium during concurrent use |
| Diuretics (furosemide, hydrochlorothiazide) | Water tablets | Excessive blood pressure lowering (first-dose hypotension), especially in dehydrated patients | Doctor may reduce or stop diuretic before starting lisinopril, or start with a lower dose |
| Gold injections (sodium aurothiomalate) | Anti-rheumatic agent | Nitritoid reactions (flushing, nausea, vomiting, hypotension) reported with concurrent ACE inhibitor use | Monitor closely; consider alternative treatment |
| mTOR inhibitors (sirolimus, everolimus, temsirolimus) | Immunosuppressants / oncology drugs | Increased risk of angioedema | Monitor closely for signs of swelling |
| Racecadotril | Antidiarrhoeal agent | Increased risk of angioedema | Use with caution; monitor for swelling |
| Vildagliptin | Diabetes medication (DPP-4 inhibitor) | Increased risk of angioedema | Be alert for signs of angioedema |
Lisinopril is frequently and safely combined with calcium channel blockers (such as amlodipine) and thiazide diuretics (such as hydrochlorothiazide) as part of an optimised blood pressure treatment regimen. Fixed-dose combinations of lisinopril with hydrochlorothiazide are widely available. However, always inform your doctor about all medications, supplements, and herbal products you are taking, including potassium-containing salt substitutes.
What Is the Correct Dosage of Lisinopril?
The usual starting dose for adults with hypertension is 10 mg once daily, with a maintenance dose of 20 mg daily and a maximum of 80 mg daily. Doses vary significantly depending on the condition being treated. Take the tablet at the same time each day with a glass of water, with or without food.
Always take lisinopril exactly as your doctor has prescribed. Do not change your dose without consulting your doctor first. Lisinopril tablets should be swallowed whole with a glass of water and can be taken with or without food. The tablets can be split in half if your doctor prescribes a half-dose. Take your tablet at approximately the same time each day for consistent blood pressure control.
Adults – High Blood Pressure (Hypertension)
Hypertension
Starting dose: 10 mg once daily
Usual maintenance dose: 20 mg once daily
Maximum dose: 80 mg once daily
Your doctor will adjust the dose gradually until your blood pressure is under control. If you are already taking a diuretic, your doctor may reduce or discontinue the diuretic before starting lisinopril, or start you on a lower dose (5 mg) to reduce the risk of first-dose hypotension.
Adults – Heart Failure
Heart Failure
Starting dose: 2.5 mg once daily
Dose titration: Increase by no more than 10 mg at a time, at intervals of at least 2 weeks
Maximum dose: 35 mg once daily
The dose is increased gradually to the highest tolerated dose. Blood pressure, kidney function, and potassium levels are monitored closely during up-titration.
Adults – After a Heart Attack
Short-Term Treatment Post-Myocardial Infarction
Day 1: 5 mg
Day 2: 5 mg
Day 3 onwards: 10 mg once daily
Treatment is typically started within 24 hours of a heart attack. If blood pressure is very low (systolic <100 mmHg), a lower starting dose of 2.5 mg may be used. Treatment continues for at least 6 weeks.
Adults – Diabetic Kidney Disease
Diabetic Nephropathy (Type 2 Diabetes with Hypertension)
Recommended dose: 10–20 mg once daily
The target dose is adjusted to achieve optimal blood pressure control while providing kidney protection. Your doctor will monitor kidney function and urinary protein levels regularly.
Children and Adolescents (6–16 years)
Hypertension Only
Children weighing 20–50 kg: Starting dose 2.5 mg once daily, maximum 20 mg daily
Children weighing over 50 kg: Starting dose 5 mg once daily, maximum 40 mg daily
Lisinopril is not recommended for children under 6 years of age or for children with severe kidney disease. The dose is determined by the child's weight and adjusted based on blood pressure response.
Elderly Patients
Elderly patients may require dose adjustments, particularly if they have impaired kidney function. Your doctor will determine the appropriate dose based on your kidney function tests and blood pressure response. Treatment is typically started at a lower dose with careful monitoring.
Patients with Kidney Impairment
Since lisinopril is excreted entirely by the kidneys, dose reduction is essential in patients with impaired kidney function. Your doctor will calculate the starting dose based on your creatinine clearance and will monitor your kidney function and potassium levels regularly throughout treatment.
Missed Dose
If you forget to take a dose, simply skip it and take your next dose at the usual time. Do not take a double dose to make up for the missed one. If you frequently miss doses, consider setting a daily alarm or taking your tablet at the same time as another daily routine (such as breakfast).
Overdose
Taking too many lisinopril tablets can cause dangerously low blood pressure (hypotension), which may lead to dizziness, fainting, circulatory shock, electrolyte imbalances, and kidney failure. Other symptoms of overdose include rapid or slow heartbeat, hyperventilation, anxiety, and cough. Seek immediate medical attention if you suspect an overdose. Contact your local emergency services or poison control centre without delay. Remember to take the medication packaging with you.
What Are the Side Effects of Lisinopril?
The most common side effects of lisinopril include dizziness, headache, dry cough, diarrhoea, vomiting, and low blood pressure when standing up (orthostatic hypotension). The dry cough is a well-known class effect of ACE inhibitors and occurs in approximately 5–10% of patients. Most side effects are mild and manageable.
Like all medicines, lisinopril can cause side effects, although not everybody gets them. Many side effects are dose-related and tend to improve as your body adjusts to the medication. If any side effects become severe, persistent, or troublesome, consult your doctor.
- Severe allergic reaction: swelling of the face, lips, tongue, throat, arms, or legs (angioedema), difficulty breathing or swallowing, hives
- Signs of serious infection: unexplained fever, sore throat, mouth ulcers (may indicate a dangerously low white blood cell count)
- Severe skin reactions: sudden onset of itching, burning, red and peeling skin
- Yellowing of the skin or whites of the eyes (jaundice), indicating possible liver damage
Common
May affect up to 1 in 10 people
- Dizziness and headache
- Low blood pressure when standing up (orthostatic hypotension), causing lightheadedness
- Dry, persistent cough (a well-known ACE inhibitor class effect)
- Diarrhoea
- Vomiting
- Reduced kidney function (usually reversible)
Uncommon
May affect up to 1 in 100 people
- Mood changes, visual or auditory hallucinations
- Numbness, tingling, or prickling sensation in the fingers
- Balance disturbances and taste disturbances
- Sleep disturbances
- Heart attack or stroke (possibly caused by excessive blood pressure lowering in high-risk patients)
- Palpitations and rapid heartbeat
- Raynaud's phenomenon (reduced blood flow to fingers and toes)
- Runny nose, nausea, stomach pain, or indigestion
- Skin rash or itching
- Erectile dysfunction
- Fatigue or weakness
- Elevated potassium, urea, creatinine, or liver enzymes in blood tests
- Severe blood pressure drop in patients with heart disease, aortic stenosis, or hypertrophic cardiomyopathy
Rare
May affect up to 1 in 1,000 people
- Changes in blood cell counts (decreased or increased values)
- Low sodium levels in the blood (hyponatraemia)
- Mental health disturbances, dry mouth
- Urticaria (hives) and hair loss
- Psoriasis
- Angioedema: swelling of the face, lips, tongue, throat, arms, or legs (patients of African descent have a higher risk)
- Acute kidney failure
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
- Gynaecomastia (abnormal breast enlargement in men)
Very Rare
May affect up to 1 in 10,000 people
- Severe bone marrow suppression: agranulocytosis, pancytopenia, severe anaemia
- Bleeding and bruising (due to low platelets)
- Swollen lymph nodes, autoimmune disease
- Bronchospasm (muscle spasm in the airways)
- Allergic pneumonitis (inflammation in the lungs) and sinusitis
- Pancreatitis or hepatitis with jaundice, liver failure
- Intestinal angioedema
- Low blood sugar (hypoglycaemia)
- Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, pemphigus
- Erythema multiforme, psoriasis-like skin reactions
- Decreased or absent urination
- Excessive sweating, cholestatic jaundice
A symptom complex of fever, muscle pain, joint pain, vasculitis (inflammation of blood vessels), elevated ESR, changes in blood values, skin rash, and photosensitivity has been reported. Side effects in children appear to be similar to those seen in adults.
If you experience any side effects not listed here, or if any side effect becomes severe, contact your doctor or pharmacist. Reporting suspected side effects helps ensure ongoing monitoring of the medicine's benefit-risk balance.
How Should You Store Lisinopril?
Store lisinopril tablets below 25°C, in the original packaging, out of the reach and sight of children. Do not use after the expiry date printed on the packaging.
Keep the tablets in their original packaging (blister pack or bottle) to protect them from moisture. Store at room temperature, not exceeding 25°C. Check the expiry date (marked "EXP" on the carton or blister) before taking any tablets. The expiry date refers to the last day of the stated month.
Do not flush unused tablets down the toilet or throw them in household waste. Return any unused or expired medication to your pharmacy for safe disposal, which helps protect the environment from pharmaceutical contamination.
What Does Lisinopril Contain?
Each lisinopril tablet contains the active ingredient lisinopril (as lisinopril dihydrate) and several standard pharmaceutical excipients. The 5 mg tablets are white and round, the 10 mg tablets are light pink and round, and the 20 mg tablets are pink and round.
Active Ingredient
The active substance is lisinopril. Each 5 mg tablet contains 5 mg lisinopril (as lisinopril dihydrate). Each 10 mg tablet contains 10 mg lisinopril (as lisinopril dihydrate). Each 20 mg tablet contains 20 mg lisinopril (as lisinopril dihydrate).
Inactive Ingredients (Excipients)
The other ingredients are: mannitol, calcium hydrogen phosphate dihydrate, pregelatinised maize starch, croscarmellose sodium, and magnesium stearate. The 10 mg and 20 mg tablets also contain iron oxide pigments (E172) for colouring. These are standard pharmaceutical excipients used to ensure proper tablet formation, disintegration, and absorption.
Sodium Content
This medicine contains less than 1 mmol (23 mg) sodium per tablet, meaning it is essentially "sodium-free". This is relevant for patients on a sodium-restricted diet.
Tablet Appearance and Packaging
5 mg tablets: White, round, flat, uncoated, 8 mm tablet with a score line on both sides.
10 mg tablets: Light pink, round, uncoated, biconvex, 7 mm tablet with a score line.
20 mg tablets: Pink, round, uncoated, biconvex, 9 mm tablet with a score line.
Available in PVC/Al blister packs and/or white HDPE bottles with PP caps and silica gel desiccant: 14, 28, 30, 50, 98, and 100 tablets. Not all pack sizes may be marketed in your country.
How Does Lisinopril Work in the Body?
Lisinopril works by inhibiting the angiotensin-converting enzyme (ACE), which prevents the formation of angiotensin II – a potent vasoconstrictor. This leads to vasodilation, reduced aldosterone secretion, and lower blood pressure. It also increases bradykinin levels, which further promotes vasodilation but is responsible for the characteristic dry cough.
The renin-angiotensin-aldosterone system (RAAS) is one of the body's most important mechanisms for regulating blood pressure and fluid balance. When blood pressure drops or the kidneys detect reduced blood flow, the kidneys release an enzyme called renin. Renin converts angiotensinogen (produced by the liver) into angiotensin I, which is then converted to angiotensin II by ACE, primarily in the lungs. Angiotensin II is a very powerful vasoconstrictor that raises blood pressure by narrowing blood vessels and stimulating the release of aldosterone from the adrenal glands, which causes the kidneys to retain sodium and water.
Lisinopril blocks the ACE enzyme, preventing the conversion of angiotensin I to angiotensin II. The result is twofold: blood vessels relax and dilate (vasodilation), and the kidneys excrete more sodium and water (due to reduced aldosterone). Together, these effects significantly lower blood pressure. In addition, by blocking ACE, lisinopril increases levels of bradykinin, a peptide that promotes vasodilation and has anti-inflammatory properties. However, accumulated bradykinin in the airways is responsible for the characteristic dry cough that affects approximately 5–10% of ACE inhibitor users.
Beyond blood pressure reduction, lisinopril has several protective effects on target organs. In the heart, it reduces afterload (the resistance the heart pumps against), improving cardiac output in patients with heart failure. It also inhibits pathological remodelling of the heart muscle after a heart attack. In the kidneys, lisinopril preferentially dilates the efferent (outgoing) arteriole of the glomerulus, reducing intraglomerular pressure and thereby slowing the progression of diabetic nephropathy and proteinuria.
Pharmacokinetic Profile
After oral administration, lisinopril is absorbed from the gastrointestinal tract with a bioavailability of approximately 25% (range 6–60%), which is not significantly affected by food. Peak plasma concentrations are reached approximately 6–8 hours after dosing. Importantly, lisinopril is the only ACE inhibitor that is not a prodrug and not metabolised by the liver – it is active in its unchanged form and is excreted entirely by the kidneys. This makes it a good choice for patients with liver impairment but means that dose adjustment is necessary in patients with kidney disease.
The effective half-life is approximately 12 hours, which allows once-daily dosing. Steady-state plasma concentrations are achieved after 2–3 days of continuous daily dosing. Lisinopril does not bind significantly to plasma proteins other than ACE itself. The onset of antihypertensive action occurs within 1–2 hours, with peak effect at 6–8 hours, and the effect is maintained for at least 24 hours.
Frequently Asked Questions About Lisinopril
Lisinopril is an ACE inhibitor used to treat high blood pressure (hypertension), heart failure, short-term treatment after a heart attack, and kidney disease in patients with type 2 diabetes and hypertension. By lowering blood pressure and protecting the heart and kidneys, lisinopril reduces the risk of stroke, heart attack, heart failure progression, and kidney failure.
The most common side effects include dizziness, headache, a persistent dry cough, diarrhoea, vomiting, and low blood pressure when standing up (orthostatic hypotension). The dry cough is a well-known class effect of ACE inhibitors, occurring in approximately 5–10% of patients. It usually resolves within 1–4 weeks of stopping the medication.
Lisinopril blocks the ACE enzyme, which is also responsible for breaking down bradykinin and substance P in the lungs. When these substances accumulate, they irritate the airways and trigger a persistent dry cough. This is a class effect of all ACE inhibitors and is not dangerous, but it can be annoying. If the cough is intolerable, your doctor may switch you to an angiotensin receptor blocker (ARB) such as losartan or valsartan, which does not cause this side effect.
No. Lisinopril must not be used during pregnancy, especially during the second and third trimesters. ACE inhibitors can cause serious harm to the developing baby, including kidney damage, low amniotic fluid, skull malformations, and in severe cases, death. If you discover you are pregnant while taking lisinopril, stop the medication immediately and contact your doctor. Safer alternatives such as labetalol, methyldopa, or modified-release nifedipine are available for blood pressure control during pregnancy.
Yes, lisinopril is commonly combined with calcium channel blockers (such as amlodipine) or thiazide diuretics (such as hydrochlorothiazide) for improved blood pressure control. However, you should generally not combine lisinopril with other drugs that block the renin-angiotensin system (ARBs such as valsartan, or the direct renin inhibitor aliskiren), as this combination increases the risk of low blood pressure, high potassium levels, and kidney damage. Always consult your doctor before combining blood pressure medications.
Lisinopril begins lowering blood pressure within 1–2 hours of the first dose, with peak effect at approximately 6–8 hours. However, the full therapeutic effect typically develops over 2–4 weeks of continuous daily dosing. Your doctor will monitor your blood pressure regularly during this period and may adjust your dose. Do not stop taking lisinopril without consulting your doctor, even if you feel well, as high blood pressure often has no symptoms.
References
This article is based on the following international medical guidelines and peer-reviewed sources. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy339
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127–e248.
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Updated 2022.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Lisinopril – Summary of Product Characteristics. EMA product information database. Accessed December 2025.
- GISSI-3 Investigators. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. The Lancet. 1994;343(8906):1115–1122.
- Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure (ATLAS study). Circulation. 1999;100(23):2312–2318.
- British National Formulary (BNF). Lisinopril. NICE BNF monograph. Accessed December 2025.
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International. 2021;99(3S):S1–S87.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in cardiology, clinical pharmacology, nephrology, and internal medicine.
Medical Writers
Board-certified physicians specialising in cardiovascular medicine, clinical pharmacology, and nephrology with documented academic and clinical experience.
Medical Reviewers
Independent review board ensuring clinical accuracy, adherence to international guidelines (ESC, AHA, NICE, WHO, KDIGO), and evidence level 1A standards.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.